Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
A study for patients with advanced solid tumors using study drug IMC-CS4
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ8124
U.S. Govt. ID: NCT01346358
Contact: Richard Carvajal: 646-317-6041 /
Additional Study Information: The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with advanced solid tumors? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Richard Carvajal